EMA Authorised: Yesafili (aflibercept) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

Yesafili is an authorised aflibercept biosimilar by Biosimilar Collaborations Ireland Limited for various retinal diseases, expanding treatment options for macu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Myopia
• Diabetes Mellitus with Complications
• Diabetic Retinopathy
• Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Yesafili (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Macular Edema;Retinal Vein Occlusion;Diabetic Retinopathy;Myopia, Degenerative;Diabetes Complications. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 25/02/2026